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Background: Differentiation and fusion of skeletal muscle myoblasts into multi-nucleated myotubes is required for
neonatal development and regeneration in adult skeletal muscle. Herein, we report novel findings that protein
kinase C theta (PKCθ) regulates myoblast differentiation via phosphorylation of insulin receptor substrate-1 and
ERK1/2.
Results: In this study, PKCθ knockdown (PKCθshRNA) myotubes had reduced inhibitory insulin receptor substrate-1
ser1095 phosphorylation, enhanced myoblast differentiation and cell fusion, and increased rates of protein synthesis as
determined by [3H] phenylalanine incorporation. Phosphorylation of insulin receptor substrate-1 ser632/635 and
extracellular signal-regulated kinase1/2 (ERK1/2) was increased in PKCθshRNA cells, with no change in ERK5
phosphorylation, highlighting a PKCθ-regulated myogenic pathway. Inhibition of PI3-kinase prevented cell
differentiation and fusion in control cells, which was attenuated in PKCθshRNA cells. Thus, with reduced PKCθ,
differentiation and fusion occur in the absence of PI3-kinase activity. Inhibition of the ERK kinase, MEK1/2, impaired
differentiation and cell fusion in control cells. Differentiation was preserved in PKCθshRNA cells treated with a MEK1/2
inhibitor, although cell fusion was blunted, indicating PKCθ regulates differentiation via IRS1 and ERK1/2, and this
occurs independently of MEK1/2 activation.
Conclusion: Cellular signaling regulating the myogenic program and protein synthesis are complex and intertwined.
These studies suggest that PKCθ regulates myogenic and protein synthetic signaling via the modulation of IRS1and
ERK1/2 phosphorylation. Myotubes lacking PKCθ had increased rates of protein synthesis and enhanced myotube
development despite reduced activation of the canonical anabolic-signaling pathway. Further investigation of
PKCθ regulated signaling may reveal important interactions regulating skeletal muscle health in an insulin
resistant state.
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Skeletal muscle development and the regeneration of adult
muscle tissue requires the completion of myogenesis: ac-
tivation, proliferation, differentiation, and fusion of mus-
cle specific stem cells, known as satellite cells [1].
Myogenesis is highly regulated by cellular, molecular,
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reproduction in any medium, provided the ormobility, cell contact, hormone sensitivity and the ex-
pression of muscle regulatory factors (i.e. MyoD, Myf5,
myogenin, and MRF5) [2,3].
Hormone signaling is critical in the regulation of skel-
etal muscle mass. Mitogenic signals from insulin and
insulin-like growth factor (IGF-1) converge on the insu-
lin receptor substrate (IRS) to regulate cell metabolism,
protein synthesis, cell survival, and cell growth by acti-
vating phosphoinositide 3-kinase (PI3-kinase)/protein
kinase B (PKB or AKT) and extracellular signal-regulated
kinase (ERK) signaling pathways [4-9]. However, theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion through these cascades, as well as the result on
myogenesis, are not completely characterized. Specifically,
PI3-kinase is a primary regulator of anabolic and catabolic
responses that contribute to the maintenance of skeletal
muscle mass, and is activated by IRS1 [10,11]. Import-
antly, the theta isoform of the protein kinase C family
(PKCθ) phospho-inhibits insulin receptor substrate-1
(IRS1) on ser1101 (homologous to ser1095 mouse num-
bering), suppressing downstream activation of AKT [12], a
target of PI3-kinase and mediator of anabolic and cata-
bolic signaling [10,11]. PKCθ also regulates skeletal muscle
regeneration in vivo [13] and myogenesis in vitro [14-16],
albeit through mechanisms that are not completely under-
stood. Therefore, further investigation into the cellular sig-
naling dynamics regulated by PKCθ will advance our
understanding of the cellular and molecular regulation of
the myogenic program.
PKC molecules are intracellular serine/threonine kinases
expressed by a variety of cell types involved in diverse
functions depending on their structure. PKC molecules
are classified as either 1) conventional, containing Ca2+
and diacylglycerol/phorbol binding domains, 2) novel,
missing the Ca2+ binding domain and 3) atypical, lacking
the Ca2+ and diacylglycerol binding domains [17]. PKCθ is
a member of the novel family of PKC molecules and is
predominantly expressed in hematopoietic [18] and skel-
etal muscle cells [19].
In skeletal muscle, PKCθ regulates, insulin sensitivity
[20-22], muscle cell proliferation and differentiation
[14,16,23], skeletal muscle regeneration [13], and expres-
sion of acetylcholine receptors in the neuromuscular
junction [24-26]. Nonetheless, the contribution of PKCθ
to myogenesis is controversial. Studies using human [23]
and chick [15] primary muscle cells showed that PKCθ
expression decreases throughout differentiation, a time
associated with increased muscle creatine kinase [15]
and desmin [14] protein levels, both of which support
differentiation and myotube formation. PKCθ was not
detected in mouse embryonic myoblasts, which were re-
sistant to the inhibitory effects of phorbol esters and
transforming growth factor beta (TGF-β) [27,28] on myo-
tube formation [29]. Genetic forced expression of PKCθ in
mouse embryonic myoblasts prevented myotube forma-
tion in the presence of TGFβ and phorbol ester [29].
Moreover, mice with dystrophic muscle have improved
skeletal muscle regeneration when PKCθ is globally absent
[13]. Taken together, these studies support that PKCθ is a
negative regulator of myogenesis and skeletal muscle re-
generation. Alternatively, primary muscle cell cultures
derived from global PKCθ knockout mice and muscle-
specific PKCθ kinase-dead mice have demonstrated a re-
quirement for PKCθ in myogenesis and regeneration
[16]. Lastly, in C2C12 muscle cells, PKCθ expressionremained constant and overexpression of PKCθ did not
impair differentiation [30].
The overall objective of this study was to investigate
how PKCθ regulates cell signaling events that contribute
to the advancement of the myogenic program. We hy-
pothesized that PKCθ negatively regulates the myogenic
program via IRS1. To test this hypothesis we used a
short hairpin-RNA (shRNA) to specifically knockdown
PKCθ expression in C2C12 cells (PKCθ
shRNA), an estab-
lished cell line for investigating the myogenic program
[8,30-32]. We then investigated how reduced PKCθ af-
fected signaling through the classical insulin signaling
pathway in addition to the affect on differentiation and
fusion of muscle myoblasts. Our data reveal a PKCθ-
regulated myogenic pathway involving serine phosphoryl-
ation of IRS1 and phosphorylation of ERK1/2 in the
control of myoblast differentiation that enhances our
understanding of how PKCθ contributes to myogenic
signaling.
Results and discussion
Knockdown of PKCθ in C2C12 cells
To investigate the mechanism by which PKCθ regulates
muscle cell differentiation and fusion, a stable PKCθ
knockdown (PKCθshRNA) cell line using C2C12 mouse
muscle cells (myoblasts) was generated by transfecting
with a PKCθ shRNA. Transfection reduced PKCθ pro-
tein and gene expression by approximately 80% com-
pared to cells transfected with scramble oligonucleotides
(scramble) (Figures 1A,C). Additionally, phosphorylation
of PKCθ was significantly reduced in PKCθshRNA
myoblasts (Figure 1B). Gene expression of PKC delta
(PKCΔ), also a member of the novel family of PKC mol-
ecules, was not different between PKCθshRNA and scram-
ble myoblasts (Figure 1D), indicating specificity of the
shRNA.
PKCθ is a negative regulator of myogenesis in C2C12
muscle cells
To determine how the loss of PKCθ affects differenti-
ation and fusion of myoblasts, PKCθshRNA and scramble
cells were exposed to differentiation media for 4 days. On
day 2, PKCθshRNA cells formed a greater number of tube-
like structures compared to scramble cells (Figure 2A, Day
2 pictures). This is in agreement with increased myogenin
transcript levels from day 1 through day 3 of differenti-
ation in PKCθshRNA cells (Figure 2B). On the fourth day,
cells were stained for myosin heavy chain (MHC) to iden-
tify differentiated cells and counterstained with DAPI to
identify nuclei (Figure 2A, Day 4). MHC protein expres-
sion via western blot (Figure 2C) and immuno staining
(Figure 2D) were markedly increased, approximately 15
fold and 2.5 fold respectively, in PKCθshRNA compared to
scramble cultures. In addition, the number of nuclei per
Figure 1 Targeted knockdown of PKCθ. A. Western blot for PKCθ in scramble and PKCθshRNA cells normalized to β-actin. ***; P<0.0001. B)Western
blot for PKCθ T538 in scramble and PKCθshRNA cells normalized to β-actin. **; P=0.0064. C) PKCθ gene expression in scramble and PKCθshRNA cells. *;
P=0.017. D) PKCΔ gene expression in scramble and PKCθshRNA cells. Data ± SEM. n=3 for all experiments.
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in PKCθshRNA cultures (Figure 2E), indicating PKCθ is a
myogenic suppressor of C2C12 myoblast differentiation
and fusion.
Focal adhesion kinase (FAK) and caveolin 3 are neces-
sary for myoblast fusion and in vivo regeneration [33,34].
Here, the gene expression of FAK (Figure 2F) and caveolin
3 (Figure 2G) were analyzed through 4 days of differenti-
ation. Interestingly, mRNA levels of FAK remained lower
in PKCθshRNA compared to scramble cells from day 1
through day 4 of differentiation (Figure 2F). Caveolin 3
mRNA levels remained similar between cell types from
day 1 through day 3 of differentiation. At day 4 of differen-
tiation, caveolin 3 levels dropped in PKCθshRNA myotubes
while increasing slightly in the scramble culture resulting
in a significant difference (Figure 2G).A decrease in FAK protein expression was reported
following 96 hours of differentiation [34], which supports
our results. Furthermore, FAK regulates the expression of
caveolin 3 [34]. Therefore, reduced expression of caveolin
3 reported here might be the result of down-regulated
FAK. The lower expression levels of both FAK and
caveolin 3 in our PKCθshRNA cells following 4 days of dif-
ferentiation support the acceleration of the fusion process
compared to scramble cultures. It is possible that FAK ex-
pression peaks in PKCθshRNA cells at an earlier time point
than analyzed here, propagating accelerated myotube de-
velopment. Alternatively, muscle cells derived from global
PKCθ knockout mice (PKCθ−/−) have impaired myogenic
properties in vitro associated with reduced FAK and
caveolin 3 [16]. Importantly, expression levels of FAK and
caveolin 3 were analyzed after 2 days in differentiation
Figure 2 PKCθ regulates the myogenic program. A) Light microscopy images taken at 10X of scramble and PKCθshRNA cells from Day 0
through Day 4 of differentiation. On Day 4 cells were stained for MHC expression (green) and nuclei counterstained with DAPI (Blue). B) Time
course of myogenin gene expression in differentiating scramble and PKCθshRNA cells. ***; P<0.0001 between scramble and PKCθshRNA cells at
indicated time points. C) MHC protein expression in scramble and PKCθshRNA day 4 myotubes normalized to β-actin. ***; P<0.0002. D) Quantification of
the density of MHC+ cells. **; P=0.0015. E) Number of nuclei per MHC+ cell. ***; P=0.0008. F) Time course of Focal adhesion kinase (FAK) gene
expression in differentiating scramble and PKCθshRNA cells. **; P<0.01 and ***; P<0.001 between scramble and PKCθshRNA at indicated time points.
G) Time course of caveolin 3 gene expression in differentiating scramble and PKCθshRNA cells. ***; P<0.001 at indicated time point. Data ± SEM.
n=3 for all experiments.
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for 4 days prior to analysis. Indeed, primary cultures de-
rived from PKCθ−/− display impaired fusion in vitro [16],
which is in contrast to our data here, derived from C2C12
cells in which shRNA was used to knockdown PKCθ ex-
pression. Although differences between a primary culture
and cell line may contribute to the desperate findings, the
in vivo milieu is complex and dynamic, and cellular inter-
actions between inflammatory and skeletal muscle cells,
two sources of PKCθ [18,19], may promote changes in
cellular function that alter ex vivo cellular dynamics. In-
flammatory cells play an integral role in regulating skeletal
muscle size [35].Primary mouse muscle cells isolated from skeletal
muscle PKCθ kinase-dead mice also have impaired myo-
genic properties and regeneration in vivo [16], contrary
to results presented in this study. Importantly, PKCθ
translocates to the nucleus in cultured human muscle
satellite cells [14] and other cell types where it directly
associates with chromatin [36]. Also, in T-cells, PKCθ
directly binds cytosolic proteins to regulate activity [37].
Together, these findings demonstrate that PKCθ has
functions beyond its kinase activity including protein-
protein interactions and protein-DNA interactions that
remain to be completely explored in skeletal muscle.
These functions of PKCθ may explain the contradictory
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models, which rely on substrate binding and availability
[16]. Indeed, mice with muscular dystrophy and the add-
itional global null mutation for PKCθ, have enhanced
skeletal muscle regeneration [13], suggesting a negative
role for PKCθ in the regulation of myogenesis. Further
work exploring the cellular and molecular interactions
of skeletal muscle PKCθ across multiple models is
warranted to more completely understand its myogenic
regulatory role.
Lack of PKCθ enhances protein synthesis apart from
classical IRS1 signaling
Our data indicates that PKCθ negatively regulates the
differentiation and fusion of myoblasts. Because PKCθ
inhibits IRS1 through serine phosphorylation and this
results in the downstream suppression of AKT [12], we
tested the hypothesis that PKCθ regulates myoblast dif-
ferentiation and fusion through altered IRS1 signaling.
IRS1 signal transduction regulates cell growth and pro-
tein synthesis through PI3-kinase/AKT activation and
the MAPK cascade involving MEK1/2/ERK signaling
[5,6,8,9,38,39]. IRS1 serine phosphorylation of specific
residues inhibits downstream signaling by preventing
IRS1 tyrosine phosphorylation [4,12,22,40]. Specifically,
phosphorylation of serine1095 (referenced as 1101 hu-
man numbering) by PKCθ impairs insulin signaling [12].
In support of our hypothesis, PKCθshRNA cells had ele-
vated rates of protein synthesis determined by [3H]
phenylalanine incorporation (Figure 3A), accompanied
by reduced IRS1 serine1095 phosphorylation following 4
days of differentiation (Figure 3C). However, myogenic
events are likely independent of insulin receptor (IR) sig-
naling because its tyrosine phosphorylation was lower in
PKCθshRNA cells (Figure 3B) despite increased differenti-
ation, fusion, and protein synthesis (Figures 2 and 3A).
Furthermore, IRS1 phosphorylation at tyrosine 1222 was
reduced in PKCθshRNA myotubes (Figure 3C). Moreover,
phosphorylation of AKT, a kinase activated in response
to IRS1/PI3-kinase signaling [4,41], was not different be-
tween cell types at serine 473, however was reduced in
PKCθshRNA myotubes at threonine 308 (Figure 3D). Lastly,
phosphorylation of mammalian target of rapamycin
(mTOR) at serine 2448, a downstream target of AKT, was
also reduced in PKCθshRNA day 4 myotubes (Figure 3E).
Collectively, our protein synthesis and immunoblot data
suggests involvement of a mechanism other than the ca-
nonical IRS1/PI3-kinase/AKT signaling pathway in pro-
moting differentiation, fusion and protein synthesis in
PKCθshRNA cells.
MAPKs participate in the regulation of a plethora of
cellular functions, including the proliferation and differ-
entiation of muscle cells and the modulation of IRS1 sig-
naling. Specifically, ERK1/2 expression increases duringdifferentiation of C2C12 cells [5,42] and permits the ex-
pression of myosin heavy chain [32]. Furthermore, ERK5
regulates myogenesis in a pathway independent of that,
which activates MyoD, and MEF2 regulated genes [8].
Moreover, MEK1/2 is a positive regulator of the muscle
specific transcription factor MyoD whose expression is
required for the initiation of myoblast differentiation [5].
ERK also reciprocally signals to IRS1 [4,40,43,44]. In 3T3-
L1 cells, IRS1 serine 636/639 phosphorylation causes IRS1
degradation [43] which is dependent on MEK1/2-induced
ERK activation in human skeletal muscle cells [45]. Finally,
in myeloma cells, ERK is phosphorylated through an
IRS1-dependent mechanism [44]. In this study, total IRS1
protein levels were markedly reduced in PKCθshRNA cells
together with increased phosphorylation of serine 632/
635 (mouse numbering homologous to human 636/639)
(Figure 3C) in day 4 myotubes, suggesting ERK-
dependent signaling. As anticipated, ERK1/2 phosphoryl-
ation was increased in PKCθshRNA cells (Figure 3F).
While ERK5 has been demonstrated to also regulate fu-
sion of C2C12 muscle cells [8], a difference in ERK5
phosphorylation between PKCθshRNA and scramble cul-
tures was not detected (Figure 3G). While phosphoryl-
ation sites on ERK5 other than those analyzed here
contribute to cell growth an survival in other cell types,
these sites have been shown regulate mitotic activity
[46,47] rather than terminal differentiation.
Interestingly, mTOR has been identified as a substrate
for ERK [48], and mTOR is required for the fusion of
differentiated skeletal muscle cells [31]. Skeletal muscle
overexpression of Rheb increased mTOR mediated kin-
ase events resulting in increased skeletal muscle size and
protein translation independent of PI3-kinase and PKB
(AKT) [49]. Here, mTOR phosphorylation was reduced
in PKCθshRNA day 4 myotubes suggesting that mTOR is
not a prime regulator of protein synthesis and myotube
development in cells lacking PKCθ at the time point
analyzed.
Our data together with prior reports [43,45] support
that lack of PKCθ in C2C12 myotubes promotes ERK1/2
mediated phosphorylation of IRS1 at serine 632/635.
While this mechanism corroborates our finding of re-
duced total IRS1 protein (Figure 3C), further work is re-
quired to determine the mechanism by which these
signaling events lead to enhanced protein synthesis.
Nonetheless, these data show a novel pathway by which
protein synthesis is increased despite reduced insulin re-
ceptor and AKT phosphorylation.
PKCθ regulates IRS1 and ERK-mediated differentiation
The purpose of these studies was to determine which ki-
nases downstream of IRS1 mediate myoblast differenti-
ation and fusion in PKCθshRNA cells. Scramble and
PKCθshRNA cells were treated with the PI3-kinase inhibitor
Figure 3 Lack of PKCθ enhances protein synthesis apart from classical IRS1 signaling. A) Rates of protein synthesis determined after 4 days
in differentiation media. **; P=0.0082. B) IR tyrosine phosphorylation normalized to total IR protein. **; P<0.0077. C) IRS1 tyrosine and serine
phosphorylation normalized to total IRS1 protein. *; P<0.05. ***; P=0.0005. D) AKT phosphorylation normalized to total AKT protein. **; P=0.0042.
E) mTOR phosphorylation normalized to total mTOR. **; P=0.0017 F) ERK1/2 phosphorylation normalized to total ERK1/2 protein. **; P=0.0023.
G) ERK5 phosphorylation normalized to total ERK5 protein. Data ± SEM. n=3 for all experiments.
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(Figure 4A) or the MEK1/2 inhibitor U0126 to inhibit
ERK activity (Figure 4B). Wortmannin completely blocked
the expression of MHC and subsequent cell fusion in
scramble cells (Figures 4B,C,D), consistent with prior re-
ports [50]. U0126 drastically reduced MHC expression
and fusion in scramble cells compared to untreated cul-
tures (Figure 2A compared to Figure 4A). However, ex-
pression of MHC was greater in U0126 compared to
wortmannin treated scramble cells, indicating a greater
degree of differentiation (Figures 4C,D). While the num-
ber of nuclei per MHC+ cell was statistically greaterin U0126 compared to wortmannin treated scramble
cultures, fewer than 2 nuclei per MHC+ cell indicates
markedly impaired fusion (Figure 4E).
Compared to wortmannin treated scramble cells,
PKCθshRNA cells had increased differentiation and main-
tained the ability to fuse despite the presence of the PI3-
kinase inhibitor (Figures 4B,C,D). Moreover, PKCθshRNA
myotubes maintained higher rates of protein synthesis
when treated with wortmannin compared to scramble cul-
tures. Specifically, in agreement with figure 3A, protein
synthesis was approximately 2-fold higher in PKCθshRNA
compared to scramble day 4 myotubes exposed to vehicle
Figure 4 PKCθ regulates IRS1 and ERK-mediated differentiation. A) Western blot analysis of AKT s473 and ERK T202/Y204 in scramble and
B) PKCθshRNAcells treated with insulin and with or without wortmannin and U0126.C) 10x immunoflourescence images of scramble and PKCθshRNA
cells treated with wortmannin and U0126 (Green; MHC and Blue; nuclei). D) Quantification of the density of MHC+ cells. *; P<0.05 and ***; P<0.0001
compared to wortmannin treated scramble cells. $; P<0.0001 compared to U0126 treated scramble cells. #; P<0.0001 compared to wortmannin treated
PKCθshRNA cells. E) Number of nuclei per MHC+ cell. ***; P<0.0001 compared to wortmannin treated scramble cells. #; P<0.0001 compared to
wortmannin treated PKCθshRNA cells. Data ± SEM. n=3 for all experiments.
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wortmannin, PKCθshRNA protein synthesis rates remained
35% higher in PKCθshRNA compared to scramble myo-
tubes (3.17 vs. 4.90 fmol/mg protein/hr; P <0.05). Thus,
PKCθshRNA cells are able to complete the myogenic pro-
gram independent of PI3-kinase signaling. These results
support our protein expression data (Figure 3) in which
reduced IR and AKT phosphorylation were found in
PKCθshRNA compared to scramble day 4 myotubes. Im-
portantly, wortmannin treatment of PKCθshRNA reduced
differentiation to levels comparable to untreated scramble
cultures (Figure 2A and Figure 4D). Therefore, while lack
or PKCθ in C2C12 myotubes is permissive for differenti-
ation despite PI3-kinase inhibition, PI3-kinase signaling
may be necessary to manifest the enhanced and acceler-
ated myotube development observed in untreated cultures.PKCθshRNA cells treated with U0126 had markedly in-
creased density of MHC+ cells (Figures 4C,D). Cell fu-
sion, on the other hand, as determined by nuclei per
MHC+ cell, was not different between PKCθshRNA and
scramble cells in the presence of the MEK inhibitor
(Figures 4C,E). There was also no difference in protein
synthesis rates between PKCθshRNA and scramble myo-
tubes treated with U0126 (4.2 vs. 5.0 fmol/mg protein/hr).
shRNA-mediate reduction of PKCθ protected muscle cell
differentiation in the presence of both PI3-kinase and
MEK1/2 inhibition, but cell fusion was protected only in
the presence of PI3-kinase inhibition. Take together, these
data show that MEK1/2 signaling is required for cell fu-
sion independently of differentiation and the expression of
PKCθ. Furthermore, our data suggests a PKCθ-specific
myogenic regulatory pathway involving IRS1 and ERK1/2
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differentiation.
Conclusions
The objective of this study was to investigate the contri-
bution of skeletal muscle cell PKCθ to signaling events
that regulate protein synthesis and myogenesis. Taken
together, our data supports a model in which PKCθ reg-
ulates IRS1 and ERK1/2 signaling that controls myoblast
differentiation and protein synthesis. Our findings that
cell fusion is equally inhibited in scramble and PKCθshRNA
myotubes treated with a MEK1/2 inhibitor suggests that
MEK signaling is required for fusion independent of
PKCθ. Additionally, abrogation of PKCθ promoted full
completion of the myogenic program and increased rates
of protein synthesis, despite reduced IR phosphorylation
and maintained higher protein synthesis rates when
treated with a PI3-kinase inhibitor. These findings demon-
strate that PKCθ may be a viable therapeutic target to pro-
mote increases in protein synthesis and promote the




C2C12 mouse muscle cells were provided by Francis X.
Pizza (University of Toledo, Dept. of Kinesiology). To
identify an siRNA to knockdown mouse PKCθ (mPKCθ)
a free Web-based tool (http://www.genelink.com/sirna/
shRNAi.asp) was used to design a putative siRNA against
the mPKCθ gene and to design oligonucleotides that en-
code a corresponding small hairpin RNA (shRNA) as pre-
viously described [51]. Origene was utilized to construct
the shRNA plasmid with oligonucleotides: ACCGTTTC
TTCGAATCGGTTTATCCAACT and the homologous
sequence. The mPKCθ shRNA construct was co-
transfected together with vectors expressing gag-pol, REV
and VSV-G into 293FT cells (Invitrogen) to generate a
third generation lentiviral construct. Transfection was
achieved using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) using 100 ng total DNA per cm2 of the growth plate
or well. The supernatants were harvested and the cell deb-
ris was removed by centrifugation at 2000 g. After addi-
tion of polybrene (5 ng/ml, Sigma Chemical Co., St. Louis,
MO), the supernatant was used to infect C2C12 cells to es-
tablish a cell line that has mPKCθ stably down regulated
(PCKθshRNA) and a scramble shRNA control. After 72
hours the cells were selected by puromycin.
Cell culture
Scramble and PKCθshRNA cells were seeded in tissue cul-
ture treated 6 well plates at equal density. They were
grown in Hyclone DMEM (Fisher Scientific) supple-
mented with antibiotics and heat inactivated HycloneFBS (Fisher Scientific) at a final concentration of 10%
(growth media). To promote myoblast differentiation
and fusion, ~90% confluent cultures were serum de-
prived by switching to DMEM containing horse serum
(Fisher Scientific) at a final concentration of 2% (differ-
entiation media). The day that growth media was re-
placed with differentiation media is considered Day 0.
Cells were maintained in differentiation media for 4 days
and then processed for immunoflourescence or protein
extraction. Media was changed every 48 hours except
when indicated.
PI3-kinase and MEK1/2 inhibition
Beginning on Day 0, scramble and PKCθshRNA cells were
incubated in differentiation media supplemented with the
PI3-kinase inhibitor wortmannin (Cayman Chemicalor the
MEK1/2 inhibitor U0126 (Cayman Chemical) at a final
concentration of 10 μM. Media was changed daily with
fresh inhibitor. Following 4 days of treatment, cells were
processed for immunoflourescence. To confirm inhibition
of PI3-kinase and MEK1/2 with wortmannin and U0126
respectively, confluent myoblasts were serum starved
overnight and treated with 10nM insulin in the presence
or absence of wortmannin or U0126. Cells were analyzed
for AKT serine 473 phosphorylation and ERK threonine
202/tyrosine 204 phosphorylation as an indicator of drug
effectiveness as described below.
Immunofluorescence
Following 4 days of differentiation, wells were washed
with PBS and fixed with cold 70% methanol/30% acetone
for 10 min at room temperature. Cells were perme-
abilized with 0.05% triton-x 100 and blocked for 30 min at
room temperature. Wells were incubated with anti-
sarcomeric myosin heavy chain (MHC) MF20 (developed
by Donald A. Fischman and obtained from the Develop-
mental Studies Hybridoma Bank, The University of Iowa,
Department of Biology, Iowa City, IA 52242) diluted 1:20
in blocking buffer for 2 hours at room temperature. Wells
were washed and incubated with goat anti-mouse FITC
secondary antibody (Invitrogen) diluted 1:200 in PBS for
30 min at room temperature. Cover slips were mounted
withVector Sheild containing 4',6-diamidino-2-phenylindole
(DAPI) (Vector Labs).
Myoblast fusion
MHC positive (MHC+) cells were viewed at 10X magni-
fication. To quantify cell fusion, 5 fields were viewed per
well in a predetermined manner by a blinded investiga-
tor; starting from the center of the well, the stage was
moved two complete fields to the right (field 1), two
fields up (field 2), four fields to the left (field 3), two
fields down (field 4), and 4 fields to the right (field 5).
For each field, one picture of MHC+ cells and one
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A blinded investigator chose 10 MHC+ cells per field.
The total number of nuclei were counted in 50 MHC+
cells per well and repeated in 3 wells for PKCθshRNA and
scramble cell lines. This yielded a total of 150 MHC+
cells analyzed for each cell line.
Myotube density
Density quantification (degree of MHC+ cell coverage of
each well) using ImagePro Plus software was performed
on images taken to determine myoblast fusion. The aver-
age MHC+ density (arbitrary units) across all 5 images
per well was determined in 3 independent wells per con-
dition and cell line.
Real time PCR
RNA was extracted using a commercially available kit
according to the manufacturer’s instructions (5 Prime).
Following quantification using a Nanodrop (Thermo
Fisher), 1ug of total RNA was reverse transcribed using
a high capacity cDNA synthesis kit (Applied Biosystems).
Real time PCR was performed on a Applied Biosystems
Step One Plus system (Applied Biosystems). Fold change
in mRNA levels was determined using 2-ΔΔ Ct with
GAPDH as a control gene. Primer sequences used were as
follows: GAPDH forward ATGTTTGTGATGGGTGTG
AA, GAPDH reverse ATGCCAAAGTTGTCATGGAT,
PKCθ forward TACATCCAGAAAAAGCCAACCA, PKCθ
reverse TTCTGTCCGCCCATTGTTCT, PKCΔ forward
GCCAGAAGTCTCTGGGAGTG, PKCΔ reverse AAAG
CTGCCTTTGCCAAGTA, myogenin forward CGCGAT
CTCCGCTACAGA, myogenin reverse TGGGACCGAAC
TCCAGTG, PTK2 (focal adhesion kinase, FAK) forward
GGTCCGACTGGAAACCAACA, FAK reverse GGCTGA
AGCTTGACACCCTC, caveolin 3 forward ACAGCTTC
GACGGTGTATGG, and caveolin 3 reverse GTGGAACA
CCCAGCAGTGTA.
Western blot
Cells were collected in lysis buffer (Final concentration:
1X RIPA buffer (Millipore), 1% triton-x100, 3% SDS)
supplemented with Halt Protease and phosphatase in-
hibitors (Pierce). Cells were lysed by continuous, vigor-
ous shaking for 20 min at 4°C. Lysates were centrifuged
and supernatants used to determine protein concentra-
tion by BCA (Pierce).
SDS-PAGE and transfer were performed as previously
described [35]. Proteins were blocked for 1 hour at room
temperature. Membranes were washed with TBS-tween
20 (0.1%) (TBST) and incubated overnight at 4°C with
either rabbit anti-mouse PKCθ (C-18; Santa Cruz) di-
luted 1:100, MHC MF20 (Developmental Studies Hy-
bridoma Bank), or one of the following from Cell
Signaling Technologies diluted 1:500: rabbit anti-mousePKCθ threonine 538, rabbit anti-mouse insulin receptor
(IR) tyrosine 1345, mouse anti-mouse total IR, rabbit
anti-mouse insulin receptor substrate 1 (IRS1) serine
1101, rabbit anit-mouse IRS1 serine 636/639, rabbit
anti-mouse IRS1 tyrosine 1222, mouse anti total IRS1,
rabbit anti-mouse AKT serine 473, rabbit anti-mouse
threonine 308, mouse anti total AKT, rabbit anti-mouse
mTOR serine 2448, mouse anti-mouse total mTOR,
mouse anti-mouse ERK1/2 threonine202/tyrosine204,
rabbit anti-mouse total ERK1/2, rabbit anti-mouse ERK5
threonine218/tyrosine 220, or rabbit anti-mouse total
ERK5. Membranes probed for total PKCθ and MHC
were normalized to mouse anti β-actin (Sigma Aldrich)
diluted 1:15,000. After washing, the membrane was incu-
bated for 2 hours at room temperature with species ap-
propriate secondary antibodies (Licor) diluted 1:5000 in
blocking buffer. Results were visualized using the Odys-
sey Imaging System (Licor). Band density was deter-
mined using Image J software and expressed as a fold
change relative to scramble. Proteins probed for phos-
phorylation were normalized to respective total protein
expression.
Protein synthesis
Following 4 days in differentiation media in the presence
or absence of wortmannin or U0126 replaced daily, cells
were incubated for 1 hour in serum-free DMEM con-
taining 2.5 mM phenylalanine and 2.5 μCi/ml [3H]
phenylalanine (Perkin Elmer, Boston, MA, USA). After
incubation, cells were washed with ice-cold PBS (pH 7.5)
and proteins were precipitated with 10% trichloroacetic
acid (TCA). An aliquot of the culture medium was saved
to determine the specific activity of the medium (c.p.m).
TCA homogenates were incubated on ice for 30 minutes;
plates were thoroughly scraped followed by centrifugation
at 4500 g for 5 min. The supernatant was discarded and
the TCA insoluble fraction was resuspended in 10% TCA,
followed by centrifugation at 4500 g for 5 min. This was
repeated four consecutive times, and the TCA insoluble
fraction was homogenized in 0.15 M NaOH at 55°C for 1
hour with frequent vortex mixing. Aliquots of each sample
were analyzed to determine the incorporated radioactivity
(c.p.m) via liquid scintillation counting using a Beckman
Coulter LS 6500. Protein content was analyzed using the
DC protein assay (Bio-Rad laboratories, Hercules, CA).
The rate of protein synthesis was calculated as femtomoles
[3H] phenylalanine per milligram of protein per hour.
Statistical analysis
Statistical analyses were performed using Graph Pad
Prism 5 software. Student’s t-Test was used to determine
differences between two means. One-Way ANOVA was
used to determine differences when more than 2 vari-
ables were compared, followed by a Bonferroni multiple
Marino et al. BMC Cell Biology 2013, 14:39 Page 10 of 11
http://www.biomedcentral.com/1471-2121/14/39comparisons post-hoc test. Analysis of gene expression
between cell types across time was performed using a
two-way ANOVA. Significance required an alpha level
of p<0.05.
Abbreviations
PKCθ: Protein kinase C theta; PKCΔ: Protein kinase C delta; IR: Insulin
receptor; IRS1: Insulin receptor substrate-1; AKT: Also known as protein kinase
B (PKB); ERK: Extracellular signal-related kinase; MEK1/2: Mitogen activated
ERK kinase; PI3-kinase: Phosphoinositide 3-kinase; mTOR: Mammalian target
of rapamycin; shRNA: Short hairpin RNA.
Competing interests
The authors declare no competing interests.
Authors’ contributions
JSM contributed to experimental design, growth and treatment of cells,
protein and gene expression analysis, and wrote the manuscript. TDH
developed the scramble and PKCθ knockdown cell lines and contributed to
experimental design. RAH performed protein synthesis experiments. EO and
JLO contributed by quantifying cell differentiation and cell fusion. AD
performed in vitro cell staining. TJM, ERS and JWH contributed to
experimental design, interpretation of data and manuscript revising. JWH
gave final approval for publication. All authors read and approved the final
manuscript.
Acknowledgments
The authors thank Francis X. Pizza (UT-Main Campus) for technical advice,
and Lance Stechschulte, and Leah Wuescher (UT-College of Medicine) for
technical assistance. The authors would like to thank Susan Tsivitse Arthur
(UNC Charlotte) for critical review of this manuscript. This work was
supported by the University of Toledo deArce-Koch award to JWH.
Author details
1Center for Diabetes and Endocrine Research, Department of Physiology and
Pharmacology, University of Toledo College of Medicine, Toledo, OH 43614,
USA. 2Department of Kinesiology, University of Toledo, Toledo, OH 43606,
USA. 3Department of Kinesiology, Laboratory of Systems Physiology,
University of North Carolina at Charlotte, Charlotte, NC 28223, USA.
Received: 11 March 2013 Accepted: 17 September 2013
Published: 21 September 2013
References
1. Hawke TJ, Garry DJ: Myogenic satellite cells: physiology to molecular
biology. J Appl Physiol 2001, 91(2):534–551.
2. Abmayr SM, Pavlath GK: Myoblast fusion: lessons from flies and mice.
Development 2012, 139(4):641–656.
3. Sabourin LA, Rudnicki MA: The molecular regulation of myogenesis.
Clin Genet 2000, 57(1):16–25.
4. Boura-Halfon S, Zick Y: Phosphorylation of IRS proteins, insulin action, and
insulin resistance. Am J Physiol Endocrinol Metab 2009, 296(4):E581–591.
5. Gredinger E, Gerber AN, Tamir Y, Tapscott SJ, Bengal E: Mitogen-activated
protein kinase pathway is involved in the differentiation of muscle cells.
J Biol Chem 1998, 273(17):10436–10444.
6. Lawlor MA, Feng X, Everding DR, Sieger K, Stewart CE, Rotwein P: Dual
control of muscle cell survival by distinct growth factor-regulated
signaling pathways. Mol Cell Biol 2000, 20(9):3256–3265.
7. Madhala-Levy D, Williams VC, Hughes SM, Reshef R, Halevy O: Cooperation
between Shh and IGF-I in promoting myogenic proliferation and
differentiation via the MAPK/ERK and PI3K/Akt pathways requires Smo
activity. J Cell Physiol 2012, 227(4):1455–1464.
8. Sunadome K, Yamamoto T, Ebisuya M, Kondoh K, Sehara-Fujisawa A,
Nishida E: ERK5 regulates muscle cell fusion through Klf transcription
factors. Dev Cell 2011, 20(2):192–205.
9. Le Grand F, Grifone R, Mourikis P, Houbron C, Gigaud C, Pujol J, Maillet M,
Pages G, Rudnicki M, Tajbakhsh S, et al: Six1 regulates stem cell repair
potential and self-renewal during skeletal muscle regeneration. J Cell Biol
2012, 198(5):815–832.10. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos
GD, Glass DJ: Mediation of IGF-1-induced skeletal myotube hypertrophy
by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001,
3(11):1009–1013.
11. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R,
Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, et al: Akt/mTOR
pathway is a crucial regulator of skeletal muscle hypertrophy and can
prevent muscle atrophy in vivo. Nat Cell Biol 2001, 3(11):1014–1019.
12. Li Y, Soos TJ, Li X, Wu J, Degennaro M, Sun X, Littman DR, Birnbaum MJ,
Polakiewicz RD: Protein kinase C Theta inhibits insulin signaling by
phosphorylating IRS1 at Ser(1101). J Biol Chem 2004, 279(44):45304–45307.
13. Madaro L, Pelle A, Nicoletti C, Crupi A, Marrocco V, Bossi G, Soddu S,
Bouche M: PKC theta ablation improves healing in a mouse model of
muscular dystrophy. PLoS One 2012, 7(2):e31515.
14. Boczan J, Biro T, Czifra G, Lazar J, Papp H, Bardos H, Adany R, Mechler F,
Kovacs L: Phorbol ester treatment inhibits proliferation and
differentiation of cultured human skeletal muscle satellite cells by
differentially acting on protein kinase C isoforms. Acta Neuropathol 2001,
102(1):55–62.
15. Kim SS, Kim JH, Kim HS, Park DE, Chung CH: Involvement of the theta-type
protein kinase C in translocation of myristoylated alanine-rich C kinase
substrate (MARCKS) during myogenesis of chick embryonic myoblasts.
Biochem J 2000, 347(Pt 1):139–146.
16. Madaro L, Marrocco V, Fiore P, Aulino P, Smeriglio P, Adamo S, Molinaro M,
Bouche M: PKCtheta signaling is required for myoblast fusion by
regulating the expression of caveolin-3 and beta1D integrin upstream
focal adhesion kinase. Mol Biol Cell 2011, 22(8):1409–1419.
17. Meller N, Altman A, Isakov N: New perspectives on PKCtheta, a member
of the novel subfamily of protein kinase C. Stem Cells 1998, 16(3):178–192.
18. Baier G, Telford D, Giampa L, Coggeshall KM, Baier-Bitterlich G, Isakov N,
Altman A: Molecular cloning and characterization of PKC theta, a novel
member of the protein kinase C (PKC) gene family expressed
predominantly in hematopoietic cells. J Biol Chem 1993, 268(7):4997–5004.
19. Osada S, Mizuno K, Saido TC, Suzuki K, Kuroki T, Ohno S: A new member of
the protein kinase C family, nPKC theta, predominantly expressed in
skeletal muscle. Mol Cell Biol 1992, 12(9):3930–3938.
20. Turban S, Hajduch E: Protein kinase C isoforms: mediators of reactive lipid
metabolites in the development of insulin resistance. FEBS Lett 2011,
585(2):269–274.
21. Wang C, Liu M, Riojas RA, Xin X, Gao Z, Zeng R, Wu J, Dong LQ, Liu F:
Protein kinase C theta (PKCtheta)-dependent phosphorylation of PDK1
at Ser504 and Ser532 contributes to palmitate-induced insulin
resistance. J Biol Chem 2009, 284(4):2038–2044.
22. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK,
Cushman SW, Cooney GJ, et al: Mechanism by which fatty acids inhibit
insulin activation of insulin receptor substrate-1 (IRS-1)-associated
phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002,
277(52):50230–50236.
23. Boczan J, Boros S, Mechler F, Kovacs L, Biro T: Differential expressions of
protein kinase C isozymes during proliferation and differentiation of
human skeletal muscle cells in vitro. Acta Neuropathol 2000, 99(2):96–104.
24. Hilgenberg L, Yearwood S, Milstein S, Miles K: Neural influence on protein
kinase C isoform expression in skeletal muscle. J Neurosci 1996,
16(16):4994–5003.
25. Miles K, Wagner M: Overexpression of nPKC theta is inhibitory for agrin-
induced nicotinic acetylcholine receptor clustering in C2C12 myotubes.
J Neurosci Res 2003, 71(2):188–195.
26. Kim S, Bondeva T, Nelson PG: Activation of protein kinase C isozymes in
primary mouse myotubes by carbachol. Brain Res Dev Brain Res 2002,
137(1):13–21.
27. Burks TN, Andres-Mateos E, Marx R, Mejias R, Van Erp C, Simmers JL, Walston
JD, Ward CW, Cohn RD: Losartan restores skeletal muscle remodeling and
protects against disuse atrophy in sarcopenia. Sci Transl Med 2011,
3(82):82ra37.
28. Burks TN, Cohn RD: Role of TGF-beta signaling in inherited and acquired
myopathies. Skelet Muscle 2011, 1(1):19.
29. Zappelli F, Willems D, Osada S, Ohno S, Wetsel WC, Molinaro M, Cossu G,
Bouche M: The inhibition of differentiation caused by TGFbeta in fetal
myoblasts is dependent upon selective expression of PKCtheta: a
possible molecular basis for myoblast diversification during limb
histogenesis. Dev Biol 1996, 180(1):156–164.
Marino et al. BMC Cell Biology 2013, 14:39 Page 11 of 11
http://www.biomedcentral.com/1471-2121/14/3930. Miles K, Wagner M: Overexpression of nPKC theta is permissive for
myogenic differentiation. J Cell Biochem 2000, 79(1):71–79.
31. Park IH, Chen J: Mammalian target of rapamycin (mTOR) signaling is
required for a late-stage fusion process during skeletal myotube
maturation. J Biol Chem 2005, 280(36):32009–32017.
32. Meissner JD, Freund R, Krone D, Umeda PK, Chang KC, Gros G, Scheibe RJ:
Extracellular signal-regulated kinase 1/2-mediated phosphorylation of
p300 enhances myosin heavy chain I/beta gene expression via
acetylation of nuclear factor of activated T cells c1. Nucleic Acids Res 2011,
39(14):5907–5925.
33. Mermelstein CS, Martins ER, Portilho DM, Costa ML: Association between
the muscle-specific proteins desmin and caveolin-3 in muscle cells.
Cell Tissue Res 2007, 327(2):343–351.
34. Quach NL, Biressi S, Reichardt LF, Keller C, Rando TA: Focal adhesion kinase
signaling regulates the expression of caveolin 3 and beta1 integrin,
genes essential for normal myoblast fusion. Mol Biol Cell 2009,
20(14):3422–3435.
35. Marino JS, Tausch BJ, Dearth CL, Manacci MV, McLoughlin TJ, Rakyta SJ,
Linsenmayer MP, Pizza FX: Beta2-integrins contribute to skeletal muscle
hypertrophy in mice. Am J Physiol Cell Physiol 2008, 295(4):C1026–1036.
36. Sutcliffe EL, Bunting KL, He YQ, Li J, Phetsouphanh C, Seddiki N, Zafar A,
Hindmarsh EJ, Parish CR, Kelleher AD, et al: Chromatin-associated protein
kinase C-theta regulates an inducible gene expression program and
microRNAs in human T lymphocytes. Mol Cell 2011, 41(6):704–719.
37. Bauer B, Krumbock N, Fresser F, Hochholdinger F, Spitaler M, Simm A,
Uberall F, Schraven B, Baier G: Complex formation and cooperation of
protein kinase C theta and Akt1/protein kinase B alpha in the NF-kappa
B transactivation cascade in Jurkat T cells. J Biol Chem 2001,
276(34):31627–31634.
38. Tureckova J, Wilson EM, Cappalonga JL, Rotwein P: Insulin-like growth
factor-mediated muscle differentiation: collaboration between
phosphatidylinositol 3-kinase-Akt-signaling pathways and myogenin.
J Biol Chem 2001, 276(42):39264–39270.
39. Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K, Moelling
K, Yancopoulos GD, Glass DJ: Differentiation stage-specific inhibition of
the Raf-MEK-ERK pathway by Akt. Science 1999, 286(5445):1738–1741.
40. Mothe I, Van Obberghen E: Phosphorylation of insulin receptor substrate-
1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin
action. J Biol Chem 1996, 271(19):11222–11227.
41. Gual P, Le Marchand-Brustel Y, Tanti JF: Positive and negative regulation
of insulin signaling through IRS-1 phosphorylation. Biochimie 2005,
87(1):99–109.
42. Lee HJ, Bae GU, Leem YE, Choi HK, Kang TM, Cho H, Kim ST, Kang JS:
Phosphorylation of Stim1 at serine 575 via netrin-2/Cdo-activated ERK1/
2 is critical for the promyogenic function of Stim1. Mol Biol Cell 2012,
23(7):1376–1387.
43. Hiratani K, Haruta T, Tani A, Kawahara J, Usui I, Kobayashi M: Roles of mTOR
and JNK in serine phosphorylation, translocation, and degradation of
IRS-1. Biochemical and biophysical research communications 2005,
335(3):836–842.
44. Purushothaman A, Babitz SK, Sanderson RD: Heparanase enhances the insulin
receptor signaling pathway to activate extracellular signal-regulated kinase
in multiple myeloma. J Biol Chem 2012, 287(49):41288–41296.
45. Bouzakri K, Roques M, Gual P, Espinosa S, Guebre-Egziabher F, Riou JP,
Laville M, Le Marchand-Brustel Y, Tanti JF, Vidal H: Reduced activation of
phosphatidylinositol-3 kinase and increased serine 636 phosphorylation
of insulin receptor substrate-1 in primary culture of skeletal muscle cells
from patients with type 2 diabetes. Diabetes 2003, 52(6):1319–1325.
46. Diaz-Rodriguez E, Pandiella A: Multisite phosphorylation of Erk5 in mitosis.
J Cell Sci 2010, 123(Pt 18):3146–3156.
47. Inesta-Vaquera FA, Campbell DG, Tournier C, Gomez N, Lizcano JM, Cuenda
A: Alternative ERK5 regulation by phosphorylation during the cell cycle.
Cell Signal 2010, 22(12):1829–1837.
48. Winter JN, Fox TE, Kester M, Jefferson LS, Kimball SR: Phosphatidic acid
mediates activation of mTORC1 through the ERK signaling pathway.
Am J Physiol Cell Physiol 2010, 299(2):C335–344.
49. Goodman CA, Miu MH, Frey JW, Mabrey DM, Lincoln HC, Ge Y, Chen J,
Hornberger TA: A phosphatidylinositol 3-kinase/protein kinase B-
independent activation of mammalian target of rapamycin signaling is
sufficient to induce skeletal muscle hypertrophy. Mol Biol Cell 2010,
21(18):3258–3268.50. Sarbassov DD, Peterson CA: Insulin receptor substrate-1 and
phosphatidylinositol 3-kinase regulate extracellular signal-regulated
kinase-dependent and -independent signaling pathways during
myogenic differentiation. Mol Endocrinol 1998, 12(12):1870–1878.
51. Hinds TD Jr, Ramakrishnan S, Cash HA, Stechschulte LA, Heinrich G, Najjar
SM, Sanchez ER: Discovery of glucocorticoid receptor-beta in mice with a
role in metabolism. Mol Endocrinol 2010, 24(9):1715–1727.
doi:10.1186/1471-2121-14-39
Cite this article as: Marino et al.: Suppression of protein kinase C theta
contributes to enhanced myogenesis In vitro via IRS1 and ERK1/2
phosphorylation. BMC Cell Biology 2013 14:39.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
